LONDON (Reuters) GlaxoSmithKline leukemia drug Arzerra, licensed from Denmark's Genmab, has been rejected by Britain's cost watchdog NICE in preliminary draft guidance.The National Institute for Health and Clinical Excellence (NICE) said on Th... national health service
To comment or read full article login. No account? Register free.